Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Open-Label, Multi-Center Study to Evaluate the Safety and Efficacy of Sunitinib Malate in Combination With AMG 386 as First Line or Second Line Therapy for Subjects With Metastatic Renal Cell Carcinoma

NCT00853372 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT00853372
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00853372 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Open-Label, Multi-Center Study to Evaluate the Safety and Efficacy of Sunitinib Malate in Combination With AMG 386 as First Line or Second Line Therapy for Subjects With Metastatic Renal Cell Carcinoma
Lead sponsor
Amgen
Phase
Phase 2
Overall status
Completed
Start date
May 28, 2009
Completion date
June 25, 2019
Enrollment
85 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

advanced renal cell carcinoma